Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening

• Egile Nagusiak: Xiaofei Chen (Egilea), Yunlong Wu (Egilea), Chun Chen (Egilea), Yanqiu Gu (Egilea), Chunyan Zhu (Egilea), Suping Wang (Egilea), Jiayun Chen (Egilea), Lei Zhang (Egilea), Lei Lv (Egilea), Guoqing Zhang (Egilea), Yongfang Yuan (Egilea), Yifeng Chai (Egilea), Mingshe Zhu (Egilea), Caisheng Wu (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2021-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Lianhuaqingwen (LHQW) capsule, a herb medicine product, has been clinically proved to be effective in coronavirus disease 2019 (COVID-19) pneumonia treatment. However, human exposure to LHQW components and their pharmacological effects remain largely unknown. Hence, this study aimed to determine hum...